NASDAQ · XOMAO

XOMA Royalty Corporation Rep 8. 375% Cumulative

$25.00 +$0.02 (+0.08%) 1D
Charting by TradingView

Key Metrics

—
Market cap
—
P/E · TTM
—
Revenue · TTM
—
Net income
EPS · TTM —
Dividend yield —
Free cash flow —
Beta · 1Y 0.06
EBITDA · TTM —
Gross margin —

Snapshot

Market cap—
Enterprise value—
Shares outstanding—
52-wk range$24.86 – $26.40
Avg volume · 20D6.2K
Net cash —
Book value / share—
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About XOMA Royalty Corporation Rep 8. 375% Cumulative
IPO dateApr 12, 2021
Employees14

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—

Profitability

Gross —
Operating —
Net —
FCF —
ROE / ROIC — · —

Financial Health

Current ratio—
Quick ratio—
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital—

Cash Flow · TTM

Operating CF —
Capex —
Free cash flow —
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

—
Needs two fiscal years of filings

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

—
Requires positive earnings and book value